Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Mt. Pleasant, South Carolina Clinical Trials

A listing of Mt. Pleasant, South Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (23) clinical trials

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

This will be a randomized, multicenter, open-label, active-controlled, efficacy, and safety study in adult hypogonadal men. The study duration is 12 months (365 days), including a 90-day, open-label efficacy period and a 9-month (275-day) safety evaluation period.

Phase

1.13 miles

Learn More »

A research study is evaluating the effects of a topical testosterone replacement therapy against placebo for men with low testosterone (hypogonadism) with a history or risk of heart disease or stroke.  

Phase N/A

1.13 miles

Learn More »

The study is evaluating the effectiveness of an investigational gel that is delivered with a pump/cap applicator for the treatment of low testosterone symptoms (such as low sex drive, low energy, mood problems, loss of muscle mass). Men who currently treat or do not treat their low testosterone are welcome ...

Phase N/A

1.13 miles

Learn More »

A research study is evaluating the combination of one investigational medication with two FDA-approved medications for high cholesterol. This research study may be an option if you: Are at least 18 years of age or older Have a history of elevated LDL (“bad” cholesterol) levels Are able to stop use ...

Phase N/A

1.13 miles

Learn More »

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease.

Phase

1.5 miles

Learn More »

Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in patients undergoing active surveillance for localized prostate cancer. ProstAtak involves the use of aglatimagene besadenovec (AdV-tk) to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the ...

Phase

6.7 miles

Learn More »

Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to ...

Phase

6.7 miles

Learn More »

Prospective Prolaris Value and Efficacy

This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-nave patients with early stage localized prostate cancer. Multiple individual VAMC sites will participate in PART 1 of the study. During PART 1 of the study, a three-part questionnaire ...

Phase N/A

7.29 miles

Learn More »

Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy

This study is for adult male patients who have recently undergone radical prostatectomy and are at high risk for relapse. The purpose of this study is to look at the effect PROSTVAC-V/F has in preventing or prolonging relapse after surgery. PROSTVAC-V/F is an investigational drug.

Phase

7.59 miles

Learn More »

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.

Phase

7.59 miles

Learn More »